ProKidney Corp.
- PROK
- NASDAQ
- Biotechnology
- Cell Therapy (RAC-T)
- Kidney Disease Therapeutics
$1.33
Today −8.59%Quote Oct 16, 2026, 08:00 PM UTC
−26.11%over the last month
Max drawdown −30.4%From 1-month high −30.4%3 months −14.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$248.1M
Approximate share count
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$4.67
+251.1% from here
Floor
$1.20
9.8% below price
Where the price sits
8 analysts
Analyst range, low to high
$3.00$6.00
- Price $1.33
- Resistance $1.38
- Consensus $4.67
Analysts' average target sits about 251% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PROKPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
231